obesity/atrophy

1. INTRODUCTION The present invention relates to the mammalian tubby (tub) genes, including the human tub gene, which are novel genes involved in the control of mammalian body weight, including recombinant DNA molecules, cloned genes or degenerate variants thereof. The present invention further

1. INTRODUCTION The present invention relates to the mammalian tubby (tub) genes, including the human tub gene, which are novel genes involved in the control of mammalian body weight, including recombinant DNA molecules, cloned genes or degenerate variants thereof. The present invention further

INTRODUCTION Age-related obesity is a health-related problem for which new treatments and methods of ameliorating, mitigating, or reversing are needed. U.S. Pat. No. 8,268,575 to Imai, S., et al. asserts that "Chemical effectors for mammalian NAD biosynthesis can mediate a variety of anti-aging

INTRODUCTION Age-related obesity is a health-related problem for which new treatments and methods of ameliorating, mitigating, or reversing are needed. U.S. Pat. No. 8,268,575 to Imai, S., et al. asserts that "Chemical effectors for mammalian NAD biosynthesis can mediate a variety of anti-aging

BACKGROUND OF THE INVENTION Obesity, defined as excess adiposity for a given body size, results from a chronic imbalance between energy intake and energy expenditure. Body mass index (BMI, kg/m.sup.2) is an accepted clinical estimate of being overweight (BMI 25 to 30) and of obesity (BMI>30). A

FIELD OF THE INVENTION The present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and for treating conditions such as cancer, arthritis, inflammatory airway disease, and metabolic disorders. More particularly, the

FIELD OF THE INVENTION The present invention relates to new melanocortin receptor ligands. These ligands are cyclic peptide analogs that preferably exhibit selectivity for the MC-4 and/or the MC-3 receptors relative to the other melanocortin receptors (in particular the MC-1 receptor). BACKGROUND OF

FIELD OF THE INVENTION The present invention concerns the preparation and uses of adamantanamines (e.g. memantine, amantadine and rimantadine) and neramexane(s) salts of thiomolybdic acids and thiotungstic acids. Their pharmaceutical compositions incorporate two complementary, bioavailable

FIELD OF THE INVENTION The subject invention relates to thiazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present

FIELD OF THE INVENTION The subject invention relates to imidazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present

FIELD OF THE INVENTION The subject invention relates to imidazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present

SUMMARY OF THE INVENTION The present invention is concerned with deuterium-enriched pyridinonecarboxamides and derivatives thereof of formula 1, ##STR00002## Wherein, R.sub.1 and R.sub.2 are independently, H, D (deuterium with enrichment of 1%-100%), F, Cl, CD.sub.3 (methyl-d.sub.3),

SEQUENCE DISCLOSURE The instant application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on May 23, 2017, is named "43257o5404.txt" and is 541,238 bytes in size. FIELD This invention

SEQUENCE DISCLOSURE The instant application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on Feb. 20, 2015, is named "43257o5402. txt" and is 541,162 bytes in size. FIELD This

SEQUENCE DISCLOSURE The instant application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on Dec. 18, 2014, is named "43257o5600.txt" and is 681,004 bytes in size. FIELD This